PubMed Health⌕ Search
Home/Archive/PubMed

PubMed · 8275433

Ifosfamide-induced hyperpigmentation.

S M Yule·A D Pearson·A W Craft
View original source ↗Export metadata ↓

Abstract

The source did not provide an abstract. Follow the original record for more information.

Explore related subjects

Antineoplastic Combined Chemotherapy ProtocolsChildChild, PreschoolEtoposideFemaleHumansHyperpigmentationIfosfamideInfantMaleSarcomaTime FactorsCommentLetter

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

S M Yule, A D Pearson, A W Craft. 1994-01-01. Ifosfamide-induced hyperpigmentation.. https://doi.org/10.1002/1097-0142(19940101)73%3A1%3C240%3A%3Aaid-cncr2820730141%3E3.0.co%3B2-6

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related citations

PubMed1999

Adjuvant therapy for gastric carcinoma patients in the past 15 years: a review of western and oriental trials.

BACKGROUND: The early detection of gastric carcinoma is neither feasible nor practiced around the world, except on a limited basis in Japan. Thus, because gastric carcinoma is detected later in most patients throughout the world, those who undergo curative resection still remain at high risk for relapse. Adjuvant therapy therefore has a potentially important place in the treatment of these patients. It has been extensively investigated in the Orient, North America, and Europe. The authors reviewed the results of these trials to determine the current status of adjuvant therapy. METHODS: All randomized studies published in the world literature since 1984 were reviewed. These studies were divided into those performed in the West and those performed in Asia and also by the type of therapy investigated (chemotherapy, chemoimmunotherapy, or radiotherapy). These findings were then summarized and tabulated. RESULTS: In the process of evaluating the results of these studies, the authors uncovered some marked differences in the methodologies employed. For example, the use of no treatment control is a norm in the West, whereas a treatment control is commonly used in Asia. In addition, there is a greater emphasis on chemoimmunotherapy in Asia than in the West. Furthermore, results of Western studies suggest that postoperative adjuvant therapy is ineffective, whereas the results of the Asian trials do not give a clear indication. Despite this, most Asian patients receive postoperative or perioperative adjuvant chemoimmunotherapy. CONCLUSIONS: Postoperative chemotherapy as an adjuvant to potentially curative resection of gastric carcinoma remains investigational despite more than 30 years of investigation in the West. Newer therapeutic combinations or strategies (preoperative chemotherapy or chemoradiotherapy) have the potential to benefit the high risk patients.

Antineoplastic Combined Chemotherapy Protocols↗
PubMed1999

A randomized clinical trial comparing concurrent and alternating thoracic irradiation for patients with limited small cell lung carcinoma. "Petites Cellules" Group.

BACKGROUND: Although thoracic radiotherapy is considered to be useful for the treatment of patients with small cell lung carcinoma (SCLC), its optimal administration schedule is still controversial. METHODS: In a multicenter clinical trial, 164 patients with limited SCLC (of whom 156 were eligible for the study) were randomized to receive either concurrent thoracic irradiation, initiated immediately after the second cycle of chemotherapy (Days 30-64) at a dose of 50 grays in 20 fractions, or alternating thoracic irradiation, scheduled in 3 courses between the second, third, fourth, and fifth cycles of chemotherapy with a 7-day rest period after and before chemotherapy at a dose of 20 grays in 8 fractions (Days 36-47 and Days 64-75) and then 15 grays in 6 fractions (Days 92-101). The same chemotherapy regimen (cyclophosphamide-doxorubicin or vindesine-etoposide) was administered every 4 weeks in both groups. RESULTS: Concurrent radiotherapy-induced lung toxicity led to early termination of this trial when a significant difference was observed (6 cases vs. 1, P = 0.05, 2-sided log rank test). Objective response rates were 89% in the 82 patients of the concurrent radiotherapy group and 95% in the 74 patients of the alternating radiotherapy group. Median survival periods were 13.5 and 14.0 months, respectively, with no significant difference between the two survival distributions (P = 0.15, 2-sided log rank test). Toxic deaths due to bone marrow hypoplasia were similar in both groups (3 vs. 2), but mortality due to lung toxicity (pulmonary fibrosis) was more frequent with concurrent radiotherapy (6 patients) than with alternating radiotherapy (1 patient) in long term analysis (P = 0.05, 2-sided log rank test). CONCLUSIONS: Although no statistically significant overall survival difference was observed between the two radiation therapy schedules, the better tolerance of the alternating schedule justifies the choice of this schedule with this chemotherapy regimen, although it may not be applicable to other chemotherapy regimens.

Antineoplastic Combined Chemotherapy Protocols↗